GlassScriptPhysician profile
Maher M Mousa
NPI 1184622243
$8,580.74
in general payments reported to CMS, 2019-2025
29 companies · $1,440 in 2025
The $1,440 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $278 · 2021: $869 · 2022: $1,695 · 2023: $2,103 · 2024: $1,647 · 2025: $1,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,155 · Education: $34.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,155.27 |
| Education | $34.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,024.05 | 2019-2025 | Tavneos, Krystexxa, Repatha |
| Otsuka America Pharmaceutical, INC. | $887.88 | 2019-2025 | Jynarque, Voyxact |
| Mallinckrodt Hospital Products INC. | $786.99 | 2020-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $732.32 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $527.84 | 2021-2024 | |
| Horizon Therapeutics Plc | $513.01 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $468.72 | 2021-2025 | Lupkynis |
| Vifor Pharma, INC. | $413.98 | 2021-2024 | Veltassa |
| Ani Pharmaceuticals, INC. | $376.84 | 2022-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $339.49 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $319.05 | 2019-2025 | Vafseo |
| Novo Nordisk INC | $309.77 | 2022-2025 | Ozempic, Rybelsus |
| Travere Therapeutics, INC. | $304.91 | 2023-2025 | Filspari |
| Daiichi Sankyo INC. | $199.86 | 2023-2025 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $177.16 | 2021-2025 | Livtencity |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $165.16 | 2020-2025 | Ultomiris |
| Nxstage Medical, INC. | $158.47 | 2023 | Liberty Select Cycler, Nxstage System One |
| Glaxosmithkline, LLC. | $154.56 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $146.18 | 2019 | |
| Fresenius USA Marketing, INC. | $140.37 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $105.22 | 2024-2025 | Prevymis, Zerbaxa, Dificid |
| Opko Pharmaceuticals, LLC | $96.18 | 2019-2024 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.18 | 2023-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $39.48 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $27.37 | 2025 | |
| Boston Scientific Corporation | $24.60 | 2024 | |
| Genentech USA, INC. | $18.64 | 2019 | |
| Ardelyx, INC. | $15.37 | 2024 | Ibsrela |
| Genzyme Corporation | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maher Mousa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.